A novel combination of abiraterone acetate and prednisolone has been shown to prolong survival in patients with hormone/castration-sensitive prostate cancer. Studies PEACE-1 and STAMPEDE found that the addition of these drugs to standard therapy lengthened survival compared to standard therapy alone.
A study by Yale-NUS researchers found that cultural backgrounds shape individuals' attitudes toward pursuing a passion as a career, affecting life outcomes. Americans tend to prioritize independence and believe passion motivates personal fulfilment, whereas Singaporeans prioritize pragmatism and view passions as potentially problematic.
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.
A Phase III trial showed a significant overall survival benefit of 63.9 months with ribociclib, compared to 51.4 months with hormone therapy alone. The estimated six-year survival rate was 44.2% with ribociclib, compared to 32% for placebo.
A simple cooling system utilizing passive solar energy and a specially designed salt can effectively cool food and living spaces without electricity. The system's two-step process involves dissolving salts in water to absorb energy, which is then regenerated using solar energy to evaporate the water.
Two phase III trials by VHIO researchers reveal significant clinical activity of trastuzumab deruxtecan in HER2-positive metastatic breast cancer, with over half of patients experiencing two years without disease progression. Trastuzumab duocarmazine also shows promise in treating HER2-negative breast cancer and other tumor types.
The MONALEESA-2 trial found that adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The combination of endocrine therapy and the CDK 4/6 inhibitor ribociclib also extends progression-free survival.